Search the Studies

73 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.

Please note that only the first 5 legal search words are being processed.

Protocol Number Title Protocol Status Min-Max Age Institute Keywords
19-C-0016Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid TumorsParticipants currently recruited/enrolled0-125 YearsNCI Hereditary Diffuse
17-C-0043Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric CancerParticipants currently recruited/enrolled2-125 YearsNCI Hereditary Diffuse
001109-CDefining the Natural History of Squamous Cell Carcinoma in Fanconi AnemiaParticipants currently recruited/enrolled8-125 YearsNCI Hereditary
000862-CHPilot Study of the Use of Functional Near-Infrared Spectroscopy (fNIRS) Combined with Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical ControlsParticipants currently recruited/enrolled0-125 YearsNICHDDiffuse
000860-CA Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas with Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) MutationsParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
000678-CRare Tumors and Cancer Predisposition in Individuals and FamiliesParticipants currently recruited/enrolled0-125 YearsNCI Hereditary
000633-CPhase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
000516-CPhase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma involving the Central Nervous SystemParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
000413-HNatural History study of CADASILParticipants currently recruited/enrolled18-100 YearsNHLBILeukoencephalopathy
000326-HA Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell MalignanciesParticipants currently recruited/enrolled18-125 YearsNHLBIDiffuse
000274-CPhase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
000193-CPhase 1 Study of Copanlisib with Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and other High-Grade B-cell LymphomasClinical hold/Recruitment or enrollment suspended18-125 YearsNCI Diffuse
000126-NA Pilot Study of NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients with Progressive Multifocal LeukoencephalopathyParticipants currently recruited/enrolled18-125 YearsNINDSLeukoencephalopathy
22-C-0004A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell CancerParticipants currently recruited/enrolled12-125 YearsNCI Hereditary
22-C-0003Feasibility of Evaluating Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisParticipants currently recruited/enrolled18-39 YearsNCI Diffuse
21-C-0014Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
20-HG-0025A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of ManNAc in Subjects with GNE MyopathyParticipants currently recruited/enrolled18-125 YearsNHGRIHereditary
20-DC-0047Natural History of Autosomal Dominant Hearing LossParticipants currently recruited/enrolled3-99 YearsNIDCDHereditary
20-C-0069A First-In-Human Phase I Single-Agent Dose-Escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
19-C-0116A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell LymphomaParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
19-C-0103A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)Participants currently recruited/enrolled18-125 YearsNCI Diffuse
18-C-0138An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma.No longer recruiting/follow-up only18-125 YearsNCI Hereditary
18-C-0080Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled TrialCompleted Study; data analyses ongoing5-125 YearsNCI Diffuse
17-C-0164A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin's LymphomaNo longer recruiting/follow-up only18-125 YearsNCI Diffuse
17-C-0149Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL),and Other Extranodal Diffuse Large B-cell LymphomasNo longer recruiting/follow-up only18-125 YearsNCI Diffuse
17-C-0137Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by Invitation3-65 YearsNCI Diffuse
17-C-0127Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
17-C-0086An Open-label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell CarcinomaNo longer recruiting/follow-up only18-125 YearsNCI Hereditary
17-C-0048Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell LymphomasCompleted Study; data analyses ongoing18-73 YearsNCI Diffuse
16-N-0072A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy with Ex Vivo Generated Polyomavirus-Specific T-cellsCompleted Study; data analyses ongoing18-125 YearsNINDSLeukoencephalopathy
16-I-0078Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME study)Participants currently recruited/enrolled18-49 YearsNIAIDDiffuse
16-C-0097Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine GliomaCompleted Study; data analyses ongoing2-21 YearsNCI Diffuse
15-H-0155Hereditary Parkinson Disease Natural History ProtocolCompleted Study; data analyses ongoing18-80 YearsNHLBIHereditary
15-C-0157Phase I/II Trial of Vandetanib in Combination with Metformin in Subjects with HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell CarcinomaCompleted Study; data analyses ongoing18-125 YearsNCI Hereditary
15-C-0078Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAsNo longer recruiting/follow-up only18-65 YearsNCI Diffuse
14-C-0157Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS LymphomaParticipants currently recruited/enrolled18-125 YearsNCI Diffuse
14-C-0156A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian CancerCompleted Study; data analyses ongoing18-125 YearsNCI Hereditary
14-C-0037A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell CancerCompleted Study; data analyses ongoing18-125 YearsNCI Hereditary
13-N-0017Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)Participants currently recruited/enrolled2-125 YearsNINDSLeukoencephalopathy
12-N-0095Clinical and Molecular Manifestations of Neuromuscular and Neurogenetic Disorders of ChildhoodParticipants currently recruited/enrolled0-125 YearsNINDSHereditary
11-HG-0218A Natural History Study of Patients with GNE Myopathy and GNE-Related DiseasesParticipants currently recruited/enrolled4-80 YearsNHGRIHereditary
11-C-0255Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni SyndromeParticipants currently recruited/enrolled0-125 YearsNCI Hereditary
11-C-0033Extended Follow-up of High Ovarian Cancer Risk Cohort from 02C0268 (GOG-199)Completed Study; data analyses ongoing18-100 YearsNCI Hereditary
10-I-0148Natural History of Severe Allergic Inflammation and ReactionsParticipants currently recruited/enrolled2-80 YearsNIAIDHereditary
10-I-0014The Natural History of Severe Viral Infections and Characterization of Immune DefectsParticipants currently recruited/enrolled2-125 YearsNIAIDHereditary
10-DK-0102Clinical and Genetic Studies in Familial Non-Medullary Thyroid CancerParticipants currently recruited/enrolled7-125 YearsNIDDKHereditary
10-C-0114A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell CancerCompleted Study; data analyses ongoing18-125 YearsNCI Hereditary
10-C-0011Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI Diffuse
07-C-0121Phase 2 Study of the C-Met RTK Inhibitor Foretinib (Formerly GSK 1363089) in Subjects with Papillary Renal Cell Carcinoma (PRC)Completed Study; data analyses ongoing18-125 YearsNCI Hereditary
07-C-0100Collection of Blood from Patients with Prostate CancerParticipants currently recruited/enrolled18-125 YearsNCI Hereditary
06-C-0219An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients with Central Nervous System TumorsCompleted Study; data analyses ongoing0-21 YearsNCI Diffuse
05-C-0252Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell LymphomasCompleted Study; data analyses ongoing18-125 YearsNCI Diffuse
04-I-0286A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease ProgressionParticipants currently recruited/enrolled1-100 YearsNIAIDHereditary
04-HG-0211Analysis of Specimens from Individuals with Pulmonary FibrosisParticipants currently recruited/enrolled18-125 YearsNHGRIHereditary
03-H-0282Characterization of Cardiac Function in Subjects with Hereditary Hemochromatosis Who Are New York Heart Association Functional Class ICompleted Study; data analyses ongoing21-100 YearsNHLBIHereditary
03-H-0105The Determination of Genetic Basis Of ImmunodeficiencyParticipants currently recruited/enrolled0-125 YearsNHLBIHereditary
03-C-0066Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal CancerParticipants currently recruited/enrolled2-125 YearsNCI Hereditary
03-AR-0131Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal StudyCompleted Study; data analyses ongoing18-125 YearsNIAMSHereditary
02-C-0268Prospective Study of Prophylactic Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian CancerCompleted Study; data analyses ongoing19-100 YearsNCI Hereditary
02-C-0212Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian CancerCompleted Study; data analyses ongoing18-100 YearsNCI Hereditary
02-C-0178Multidisciplinary Etiologic Study of Familial Testicular CancerNo longer recruiting/follow-up only12-125 YearsNCI Hereditary
02-C-0052Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History StudyParticipants currently recruited/enrolled0-125 YearsNCI Hereditary
01-N-0206Phenotype/Genotype Correlations in Movement DisordersParticipants currently recruited/enrolled2-125 YearsNINDSHereditary
01-DC-0229Genetic Analysis of Hereditary Disorders of Hearing and BalanceCompleted Study; data analyses ongoing0-99 YearsNIDCDHereditary
01-DC-0228Clinical and Molecular Analysis of Enlarged Vestibular AqueductsCompleted Study; data analyses ongoing0-99 YearsNIDCDHereditary
01-CC-0045Studies of Phlebotomy Therapy in Hereditary HemochromatosisParticipants currently recruited/enrolled18-125 YearsCC Hereditary
01-C-0030Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated LymphomasNo longer recruiting/follow-up only18-125 YearsNCI Diffuse
00-N-0043Clinical and Molecular Manifestations of Inherited Neurological DisordersParticipants currently recruited/enrolled2-125 YearsNINDSHereditary
00-H-0051Cutaneous Tumorigenesis in Patients with Tuberous SclerosisParticipants currently recruited/enrolled18-90 YearsNHLBIHereditary
97-C-0147Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant DiseasesParticipants currently recruited/enrolled2-125 YearsNCI Hereditary
93-C-0133Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkin's LymphomaNo longer recruiting/follow-up only12-125 YearsNCI Diffuse
89-C-0086Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant DisordersParticipants currently recruited/enrolled2-125 YearsNCI Hereditary
78-C-0039Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of CancerNo longer recruiting/follow-up only0-125 YearsNCI Hereditary
10 Center Drive,Bethesda, MD 20892 | Directions
Privacy Statement | Accessibility | Plain Language | FOIA | Disclaimer
Clinical Center | National Institutes of Health | HHS Vulnerability Disclosure | U.S. Department of Health and Human Services | USA.gov
NIH…Turning Discovery Into Health®